Sernova Appoints Christopher Barnes as Vice President, Investor Relations and Grant Options / DSUs

0

LONDON, ONTARIO – December 14, 2021 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE / XETRA: PSH), a clinical-stage leader in regenerative medicine and cell therapy developing a potential ‘functional cure’ ‘for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce today the appointment of Christopher Barnes as Vice President of Investor Relations. Mr. Barnes will lead the execution of Sernova’s investor relations strategy and communications activities.

New VP Investor Relations

Mr. Barnes has 23 years of experience in investor relations and capital markets. His previous investor relations experience includes serving as an investor relations manager at a large North American healthcare company. In addition, he has worked in capital markets and institutional sales for three boutique investment brokers covering purchase accounts in Canada, the United States and Europe. “We are delighted to welcome Christopher Barnes, senior director of investor relations and financial markets, to the management team of Sernova,” commented Dr. Philip Toleikis, President and CEO. “The continued success of our peer-competitive Cell Pouch System ™ diabetes clinical program and our evolving global pharmaceutical partnership activities are drawing the attention of institutional and other investors. Christopher’s strong network of relationships across the North American investor community, combined with his capital market knowledge and communications experience will accelerate and broaden awareness of Sernova’s perspectives, developing the platform the most clinically successful in the cell therapy industry to date, with the longest-treated patient in our T1D study now insulin independent for over 20 months. He will work closely with our new York, US-based LifeSci Advisors team to strengthen targeted investor outreach and other new initiatives, as well as transition our shareholder base to institutional shareholders. . “

The appointment of Mr. Barnes continues to strengthen the management and internal clinical and regulatory, R&D and corporate teams of Sernova to support and continue the execution of the Company’s growth plan.

Option and DSU grants

Along with the expansion of the team and the recognition of Sernova’s significant achievements and transformation over the past two years, Sernova’s board of directors has granted 13,575,484 stock options to certain officers, employees and consultants of the Company, each option being exercisable in one common share. at a price of $ 1.32 per share for a period of 5 years, and granted 1,360,000 deferred share units (DSUs) to its non-management directors. The last company wide option and DSU grants were made two years ago in 2019.

ABOUT SERNOVA Sernova develops regenerative medicine therapeutic solutions using medical device (Cell Pouch) and immune-protected therapeutic cells / tissues (i.e. with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders, including including hemophilia, and other diseases treated by cellular production of missing or insufficient proteins or hormones in the body For more information, please visit www.sernova.com.

ABOUT THE SERNOVA CELL POUCH SYSTEM

The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, and implantable macroencapsulation device solution designed for long-term survival and function of therapeutic cells. The device during implantation is designed to incorporate into the tissue, forming highly vascularized tissue chambers for transplantation and therapeutic cell function, which then release proteins and hormones as needed to treat the disease.

The cell pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been shown to provide a biologically compatible environment for producer cells. insulin in humans for a first in Canada. study in humans. Sernova is currently conducting a Phase I / II study at the University of Chicago. The first positive results were presented at several international scientific conferences.

FOR MORE INFORMATION, PLEASE CONTACT:

Corey Davis, Ph.D. LifeScience Advisors, LLC [email protected] Tel. : 212-915-2577

Christopher Barnes Vice President, Investor Relations Sernova Corp. [email protected] Tel. : 519-902-7923 www.sernova.com

FORWARD-LOOKING INFORMATION This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute “forward-looking statements” that involve various risks, uncertainties and assumptions, including, without limitation, statements. regarding the outlook, plans, and goals of the business. Where possible, but not always, words such as “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “The potential of” and similar expressions, or that events or conditions “will”, “would”, “could”, “could” or “should” occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date these statements were made. Many factors could cause Sernova’s actual results, performance or achievements to be not as anticipated, estimated or anticipated or to differ materially from those expressed or implied by the forward-looking statements contained in this press release. Such factors could include, but are not limited to, the Company’s ability to obtain additional financing and licensing agreements on reasonable terms, if at all; ability to conduct all preclinical and clinical studies required for the Company’s Cellular Pocket System and / or associated technologies, including the timing and results of such trials; ability to obtain all necessary or timely regulatory approvals; ability to sub-license additional complementary technologies; ability to execute business strategy and compete successfully in the market; and the inherent risks associated with the development of combination biotechnology products in general. Many factors are beyond our control, including those caused by, related to or impacted by the novel coronavirus pandemic. Investors should consult the Company’s quarterly and annual documents available at www.sedar.com for additional information on the risks and uncertainties relating to forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


Source link

Share.

Comments are closed.